Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Neurosense Therapeutics Ltd. ( (NRSN) ) has provided an announcement.
On February 9, 2026, NeuroSense Therapeutics said the Australian Patent Office granted a new patent covering the composition of its lead ALS and Alzheimer’s candidate, PrimeC, extending exclusivity for the therapy in that market through October 2042. The patent builds on earlier U.S. protection and is positioned as a key element in the company’s strategy to secure durable global IP around PrimeC as it advances toward Phase 3 development in ALS and potential commercialization across major neurodegenerative indications.
The company highlighted that PrimeC’s synchronized, extended-release formulation differentiates it from simple co-administration of its components, aiming to modulate neuroinflammation, iron dysregulation and miRNA pathways implicated in ALS progression. By reinforcing its patent estate in another key jurisdiction, NeuroSense is seeking to underpin long-term value creation and competitive positioning in a field marked by limited disease-modifying treatments and significant unmet patient need.
The most recent analyst rating on (NRSN) stock is a Hold with a $0.90 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, widening losses, and increasing cash burn), which elevates funding and dilution risk. Technical signals are mixed with a weak longer-term trend despite neutral momentum, and valuation is limited by negative earnings and no dividend support.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing combination therapies for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s and Parkinson’s. The company’s lead candidate, PrimeC, is an extended-release oral fixed-dose combination of ciprofloxacin and celecoxib designed to target multiple disease mechanisms in ALS and Alzheimer’s.
Average Trading Volume: 334,977
Technical Sentiment Signal: Sell
Current Market Cap: $27.91M
For an in-depth examination of NRSN stock, go to TipRanks’ Overview page.